Session VI: Colorectal Cancer I
FULL ABSTRACTS AVAILABLE SATURDAY JULY 4
Late-Breaking Abstract-7: Encorafenib (ENCO) plus Cetuximab (CETUX) With or Without Binimetinib (BINI) for BRAFV600E Metastatic Colorectal Cancer (mCRC): Relationship Between Carcinoembryonic Antigen (CEA), and Clinical Outcomes from BEACON CRC
Merck Satellite Symposium:
Meet the Experts: Role of Anti-EGFRs beyond the First Line (1L) - Later Line Treatment Opportunities
Webcast from Wednesday, July 1 (Needs registration at WCGIC)
Short Oral-18: Single-arm multicentre phase II study of bevacizumab (B) combined with 9-weekly alternating CAPOX and CAPIRI as first-line treatment of patients with metastatic colorectal cancer (mCRC): main results of the AXOAXI-trial
P-18 REMARRY and PURSUIT trials: Liquid biopsy-guided re-challenge of anti-EGFR monoclonal antibody for patients with RAS/BRAF V600E wild-type metastatic colorectal cancer (Abstract on page S95) ongoing study
Short Oral-23: Prognostic impact of microsatellite instability/mismatch repair deficiency on patients with stage III colon cancer and stage IV colorectal cancers (CRC): analysis of 42,984 Patients in the National Cancer Database (NCDB)
Posters with trifluridine/tipiracil
PD-7 Updated survival analysis of the Danish randomized study comparing trifluridine/tipiracil with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer (abstract on page S214)
The authors conclude that updated survival analyses confirm that FTD/TPI in combination with bevacizumab prolongs PFS and OS and is a new valuable option in patients with chemo-refractory mCRC. Results on markers for no benefit and time to deterioration of performance status will be presented.
The authors conclude that their real-life single-center results show that regorafenib and trifluridine/tipiracil have similar efficacy and safety among the Bulgarian population compared with previously acquired global data.
The authors conclude that their data show that treatment with trifluridine/tipiracil in daily clinical practice is feasible and safe. Forty-eight patients (39%) achieved clinical benefit with trifluridine/tipiracil. Patient characteristics such as left side primary tumor location, WT KRAS status, WT BRAF status, more than 3 lines of previous treatment, ECOG PS 0, and Platelet-to-Lymphocyte Ratio.
The authors conclude that comparing their data with those of the RECOURSE study, they can say that the SG and PFS of their patients were significantly lower. This may be due to the fact that they included patients with ECOG 2, rapid progressors, as well as a higher percentage of patients who required hospital admission due to toxicity. The adverse events of their patients were similar to those described in the RECOURSE study, except for asthenia and febrile neutropenia, which were significantly higher in their study.
P-190 A retrospective study of regorafenib versus trifluridine/tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: Multi-institution real-life clinical data (Abstract on page 152)
The authors conclude that no significant difference between regorafenib and TAS-102 sequence treatments was observed in patients with mCRC. Further analyses are ongoing to potentially identify a biomarker or a clinical sub-group to distinguish the two drugs.
The authors aimed to investigate the outcomes and safety of TAS-102 treatment in a real-world setting. Their results, being comparable with previously reported studies, further demonstrate the clinical benefit of TAS-102 for refractory mCRC patients with manageable toxicities. Furthermore, the benefit was derived regardless of tumor characteristics or previous treatment received.
The authors conclude that their RWD on TFT was associated with a better OS than expected. This RWD study was able to validate GPC, GPC with no liver metastases and grade